Lack of predictive factors for the clinical course of bullous pemphigoid.
BACKGROUND
Bullous pemphigoid is a clinically heterogeneous disease although little is known of the factors affecting its course and outcome.


OBJECTIVE
Our purpose was to document the clinical course, outcomes, and causes of death in treated bullous pemphigoid and to determine the predictive factors affecting outcome.


METHODS
The clinical course was documented in 82 patients with immunologically proven bullous pemphigoid (mean follow-up 3 years 2 months). To identify factors predictive of outcome, 16 patients with "good prognosis bullous pemphigoid" (no systemic treatment or in remission within 2 years) were compared with 12 patients with recurrent disease requiring maintenance therapy who still needed treatment after 3 years or longer. Remission was defined as 3 months free of lesions, without systemic treatment.


RESULTS
The disease duration varied from 9 weeks to 17 years (estimated median treatment time 2 years 1 month). Of patients followed up for at least 2 years, 30% achieved remission and by 3 years the remission rate was 50%. Two patients had a subsequent relapse (9%). The mortality rate at 1 year was 19%, and treatment was believed to be contributory in seven deaths. No clinical, immunologic, or immunogenetic factors were predictive of disease duration.


CONCLUSIONS
Despite the heterogeneity of the clinical course and duration of bullous pemphigoid, no predictive factors are recognized.
Venning
V A
VA
Department of Dermatology, Slade Hospital, Oxford, United Kingdom.
Wojnarowska
F
F
D000368:Aged; D000369:Aged, 80 and over; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000401:mortality; D001379:Azathioprine / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010391:Pemphigoid, Bullous / Q000188:drug therapy* / Q000401:mortality; D011239:Prednisolone / Q000627:therapeutic use*; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome
D003622:Dapsone; D011239:Prednisolone; D001379:Azathioprine